Establishment of pemetrexed-resistant non-small cell lung cancer cell lines

Cancer Letters

Volumn 309, Issue 2, 2011, Pages 228-235

  Zhang, Dan ^a   Ochi, Nobuaki ^a   Takigawa, Nagio ^b   Tanimoto, Yasushi ^a   Chen, Yanyan ^a   Ichihara, Eiki ^a   Hotta, Katsuyuki ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Non small cell lung cancer; Pemetrexed; Resistance; Thymidylate synthase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; DIHYDROFOLATE REDUCTASE; DOCETAXEL; FLUOROURACIL; IRINOTECAN; METHOTREXATE; NAVELBINE; PEMETREXED; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DHFR GENE; GARFT GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; TS GENE; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; FOLIC ACID ANTAGONISTS; GENE EXPRESSION; GLUTAMATES; GUANINE; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAXOIDS; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; VINBLASTINE;

EID: 79960835886     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.006     Document Type: Article

References (24)

1. Kris M.G., Benowitz S.I., Adams S., Diller L., Ganz P., Kahlenberg M.S., Le Q.T., Markman M., Masters G.A., Newman L., Obel J.C., Seidman A.D., Smith S.M., Vogelzang N., Petrelli N.J. Clinical cancer advances 2010: annual report on progress against cancer from the american society of clinical oncology. J. Clin. Oncol. 2010, 28:5327-5347.
2. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., Shackelford K.A., Mendelsohn L.G., Soose D.J., Patel V.F., Andis S.L., Bewley J.R., Rayl E.A., Moroson B.A., Beardsley G.P., Kohler W., Ratnam M., Schultz R.M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997, 57:1116-1123.
3. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metast. Rev. 2007, 26:153-181.
4. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 2002, 346:92-98.
5. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., Nishiwaki Y., Saijo N., Ariyoshi Y., Fukuoka M. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann. Oncol. 2007, 18:317-323.
6. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J.S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., de Marinis F., Simms L., Sugarman K.P., Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008, 26:3543-3551.
7. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., Gatzemeier U., Tsao T.C., Pless M., Muller T., Lim H.L., Desch C., Szondy K., Gervais R., Shaharyar, Manegold C., Paul S., Paoletti P., Einhorn L., Bunn P.A. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004, 22:1589-1597.
8. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., Wu Y.L., Bover I., Begbie S., Tzekova V., Cucevic B., Pereira J.R., Yang S.H., Madhavan J., Sugarman K.P., Peterson P., John W.J., Krejcy K., Belani C.P. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
10. Kohara H., Tabata M., Kiura K., Ueoka H., Kawata K., Chikamori M., Aoe K., Chikamori K., Matsushita A., Harada M. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line. Clin. Cancer Res. 2002, 8:287-292.
11. Sigmond J., Backus H.H., Wouters D., Temmink O.H., Jansen G., Peters G.J. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem. Pharmacol. 2003, 66:431-438.
12. Longley D.B., Harkin D.P., Johnston P.G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3:330-338.
13. Ozasa H., Oguri T., Uemura T., Miyazaki M., Maeno K., Sato S., Ueda R. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci. 2010, 101:161-166.
14. Uemura T., Oguri T., Ozasa H., Takakuwa O., Miyazaki M., Maeno K., Sato S., Ueda R. ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010, 101:2404-2410.
15. Hanauske A.R., Eismann U., Oberschmidt O., Pospisil H., Hoffmann S., Hanauske-Abel H., Ma D., Chen V., Paoletti P., Niyikiza C. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest. New Drugs 2007, 25:417-423.
16. Giovannetti E., Mey V., Nannizzi S., Pasqualetti G., Marini L., Del Tacca M., Danesi R. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol. Pharmacol. 2005, 68:110-118.
17. Longley D.B., Ferguson P.R., Boyer J., Latif T., Lynch M., Maxwell P., Harkin D.P., Johnston P.G. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin. Cancer Res. 2001, 7:3533-3539.
18. Saga Y., Suzuki M., Mizukami H., Urabe M., Fukushima M., Ozawa K., Sato I. Enhanced expression of thymidylate synthase mediates resistance of uterine cervical cancer cells to radiation. Oncology 2002, 63:185-191.
19. Seiwert T.Y., Connell P.P., Mauer A.M., Hoffman P.C., George C.M., Szeto L., Salgia R., Posther K.E., Nguyen B., Haraf D.J., Vokes E.E. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin. Cancer Res. 2007, 13:515-522.
20. Brade A., Bezjak A., Macrae R., Laurie S., Sun A., Cho J., Leighl N., Pearson S., Southwood B., Wang L., McGill S., Iscoe N., Shepherd F.A. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010.
21. Cardenal F., Arnaiz M.D., Moran T., Jove J., Nadal E., Porta R., Sole J.M., Brao I., Palmero R., Fuentes R., Nunez I., Caveda E., Cassinello A. Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. Lung Cancer 2011.
22. Zhao R., Hanscom M., Chattopadhyay S., Goldman I.D. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway. Cancer Res. 2004, 64:3313-3319.
23. Wang Y., Zhao R., Goldman I.D. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem. Pharmacol. 2003, 65:1163-1170.
24. Wu M.F., Hsiao Y.M., Huang C.F., Huang Y.H., Yang W.J., Chan H.W., Chang J.T., Ko J.L. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J. Thorac. Oncol. 2010, 5:1143-1151.